摘要
目的探讨阿托伐他汀联合甲钴胺对脑梗死患者同型半胱氨酸、血脂和神经功能的调控作用。方法选取我院收治的确诊为脑梗死患者80例,按照随机数字表法均分为观察组和对照组,对照组给予常规治疗+口服阿托伐他汀,观察组在对照组的基础上口服甲钴胺片。分别检测2组患者的同型半胱氨酸和血脂水平,评价神经功能,进行统计学分析。结果治疗前2组各指标差异无统计学意义;治疗3,7和14d后,观察组Hcy、胆固醇、三酰甘油和低密度脂蛋白水平均较治疗前降低,且观察组低于对照组,其组内和组间差异均有统计学意义(P<0.05);高密度脂蛋白水平治疗后高于治疗前,且观察组高于对照组(P<0.05)。观察组治疗后1年内神经功能缺损评分低于对照组(P<0.05)。结论阿托伐他汀联合甲钴胺可降低脑梗死患者同型半胱氨酸和血脂水平,改善患者预后和神经功能,值得临床推广。
Objective To investigate the effects of atorvastatin combined with mecobalamin in patients with cerebral infarction,and to study the regulation effect of homocysteine and blood lipids.Methods 80 cases of cerebral infarction in our hospital were randomly divided into observation group and control group.Patients in the control group were given conventional therapy plus atorvastatin orally,while the observation group were given Mecobalamin Tablets orally on the basis of the control group administration.Homocysteine and lipid were detected,statistically analyzed.Results The difference between the two groups before the treatment all indexes had no statistical significance(P〈0.05);but after treated for 3,7and 14 days,homocysteine,cholesterol,triglyceride,low density lipoprotein levels and high density lipoprotein levels showed statistically significant difference between the groups(P〈0.05).Conclusion Atorvastatin combined with Mecobalamine Injections can reduce the homocysteine and lipid levels of patients with cerebral infarction,improve the prognosis of patients,and is worthy of clinical promotion.
出处
《西北药学杂志》
CAS
2016年第3期313-315,共3页
Northwest Pharmaceutical Journal